Commonwealth of Pennsylvania Public School Empls Retrmt SYS Cuts Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,052 shares of the medical device company’s stock after selling 4,182 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in DexCom were worth $6,459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Teacher Retirement System of Texas increased its stake in DexCom by 269.4% during the fourth quarter. Teacher Retirement System of Texas now owns 28,759 shares of the medical device company’s stock worth $2,237,000 after purchasing an additional 20,974 shares during the period. Royal London Asset Management Ltd. increased its stake in shares of DexCom by 4.7% during the fourth quarter. Royal London Asset Management Ltd. now owns 170,949 shares of the medical device company’s stock worth $13,295,000 after buying an additional 7,711 shares during the period. Harvest Fund Management Co. Ltd increased its stake in shares of DexCom by 42.5% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 26,307 shares of the medical device company’s stock worth $2,013,000 after buying an additional 7,848 shares during the period. Vinva Investment Management Ltd purchased a new stake in shares of DexCom during the fourth quarter worth approximately $1,030,000. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its stake in shares of DexCom by 107.9% during the fourth quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 6,855 shares of the medical device company’s stock worth $533,000 after buying an additional 3,558 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

DXCM stock opened at $73.80 on Friday. The company has a market capitalization of $28.84 billion, a P/E ratio of 51.61, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The business has a 50 day simple moving average of $83.33 and a 200-day simple moving average of $76.98. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on DXCM shares. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group upped their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.